ImmuCell Corporation (NASDAQ: ICCC) is a Healthcare company (Biotechnology) with a market capitalization of $103M. The Maz Rating grades it against the other companies in its sector.
ImmuCell Corporation's current Maz Rating and its five factor grades are for members: log in to see them.
At $11.33, ImmuCell Corporation trades at 56.9x trailing earnings, 3.1x sales and 3.2x book value, with an EV/EBITDA of 24.0. Over the last twelve months it generated about $33M of revenue and $2M of net income. It runs a gross margin of 40.8%, an operating margin of 14.5% and a net margin of 5.7%. It shows return on equity of 6.2%, return on invested capital of 10.5% and a free cash flow yield of 5.2%. On the balance sheet: a debt-to-equity ratio of 0.37 and a current ratio of 4.61. Over the past 52 weeks the share price ranged from $4.52 to $12.10, with a beta of 0.62.
ImmuCell Corporation does not currently pay a dividend.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.